Published online before print May 24, 2001, doi: 10.1161/hh1101.091267
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2001 American Heart Association, Inc.
Molecular Medicine |
Gene Transfer of Dominant-Negative Mutants of Extracellular Signal–Regulated Kinase and c-Jun NH2-Terminal Kinase Prevents Neointimal Formation in Balloon-Injured Rat Artery
From the Department of Pharmacology (Y.I., S.K., M.N., H.Y., Y.Z., H.I.), Osaka City University Medical School, Osaka; the Gene Experiment Center and Center for Tsukuba Advanced Research Alliance (H.M.), University of Tsukuba; First Department of Internal Medicine (M.H.), Osaka Medical College, Osaka; and Institute for Cellular and Molecular Biology (Y.K.) and Department of Geriatric Medicine (R.M.), Osaka University Medical School, Osaka, Japan.
Correspondence to Shokei Kim, MD, Department of Pharmacology, Osaka City University Medical School, 1-4-3 Asahimachi, Abeno, Osaka 545-8585, Japan. E-mail kims{at}med.osaka-cu.ac.jp
Abstract
Abstract—We previously reported that extracellular signal–regulated kinase (ERK) and c-Jun NH2-terminal kinase (JNK), belonging to mitogen-activated protein kinases, are rapidly activated in balloon-injured artery. Therefore, we examined the role of these kinase activations in neointimal formation by using an in vivo gene transfer technique. We made the dominant-negative mutants of ERK (DN-ERK) and JNK (DN-JNK) to specifically inhibit endogenous ERK and JNK activation, respectively. Before balloon injury, these mutants were transfected into rat carotid artery using the hemagglutinating virus of Japan liposome method. In vivo transfection of DN-ERK and DN-JNK significantly suppressed the activation of ERK and JNK, respectively, after balloon injury, confirming successful expression of the transfected genes. Neointimal formation at 14 and 28 days after injury was prevented by gene transfer of DN-ERK or DN-JNK. Furthermore, bromodeoxyuridine labeling index and total cell–counting analysis at 7 days showed that either DN-ERK or DN-JNK remarkably suppressed smooth muscle cell (SMC) proliferation in both the intima and the media after injury. Gene transfer of wild-type ERK (W-ERK) or JNK (W-JNK) significantly enhanced neointimal hyperplasia at 14 days after injury. Furthermore, DN-ERK and DN-JNK significantly suppressed serum-induced SMC proliferation in vitro. We obtained the first evidence that in vivo gene transfer of DN-ERK or DN-JNK prevented neointimal formation in balloon-injured artery by inhibiting SMC proliferation. Thus, ERK and JNK activation triggers SMC proliferation, leading to neointimal formation. These kinases may be the new therapeutic targets for prevention of vascular diseases.
Key Words: balloon • signal transduction • muscle, smooth • remodeling
Balloon injury causes vascular smooth muscle cell (SMC) proliferation and migration and the accumulation of extracellular matrix, which finally result in the neointimal formation.1 2 Accumulating evidence indicates that intimal thickening by balloon injury is mediated by a complex interaction of a variety of growth-regulatory molecules, such as growth factors, vasoactive peptides, inflammatory cytokines, or chemokines.3 4 5 These molecules are therefore regarded as the useful target for treatment of vascular thickening. However, it has been recently proposed that targeting the critical intracellular signaling steps common to the induction and action of these growth-regulatory molecules may be more useful than the inhibition of a single growth-regulatory pathway, and this notion is supported by recent experimental findings on the prevention of neointimal hyperplasia by in vivo transfer of antisense cdc2 kinase and proliferating cell nuclear antigen oligonucleotides or retinoblastoma protein RB, cyclin kinase inhibitor protein p21, or the dominant-negative mutant of ras gene, as reviewed.6 7 8 Despite the critical and diverse role of intracellular protein kinase cascades in cellular responses by the above-mentioned neointima-generating molecules, the role of the protein kinases in vascular thickening remains to be determined.
Extracellular signal–regulated kinase (ERK) and c-Jun NH2-terminal kinase (JNK), belonging to the mitogen-activated protein kinase (MAPK) family, are commonly activated by vascular remodeling–related molecules and play the central role in the initiation of cellular responses, including cellular gene expression, growth, migration, or apoptosis.9 10 11 Furthermore, the possible role of these MAPKs in various cardiovascular diseases has been proposed, as reviewed.11 Recently, we12 and other groups of investigators13 14 have found that both ERK and JNK are rapidly and transiently activated in balloon-injured artery. Despite the in vitro evidence for the involvement of ERK in cultured vascular smooth muscle cell (SMC) proliferation, in vivo administration of PD98059, a selective inhibitor of MAPK/ERK-1 (MEK1), in balloon-injured rat artery failed to prevent intimal SMC proliferation, suggesting no contribution of ERK to intimal hyperplasia.14 Thus, the role of ERK in the neointima formation in vivo is unclear. Accumulating in vitro evidence indicates that JNK is implicated in various, often opposing cellular responses, as reviewed.15 For example, there is considerable evidence that JNK activation promotes cell apoptosis, whereas there are also many reports that JNK activation instead inhibits cell apoptosis and promotes cell proliferation or differentiation. Thus, JNK has diverse functions, and its function strongly depends on the cell type and the context of other regulatory influences that the cell is receiving. However, as in the case of ERK, the in vivo role of JNK activation in vascular diseases remains to be elucidated.
In the present study, to elucidate the role of increased ERK and JNK activities after balloon injury, dominant-negative mutants of ERK and JNK were produced and in vivo transfected into rat carotid artery before balloon injury using the gene-transfer method with hemagglutinating virus of Japan (HVJ).16 17 18 19 20 We obtained the first evidence that both ERK and JNK are directly involved in neointimal formation after balloon injury.
Materials and Methods
Animals
All procedures were in accordance with institutional
guidelines for animal research. Nine- to ten-week-old male
Sprague-Dawley rats (Clea Japan, Tokyo, Japan) weighing 
300 to
350 g were used.
Dominant-Negative Mutant of ERK and JNK
Rat wild-type p44ERK cDNA (W-ERK) and p46JNK
cDNA(W-JNK) were produced by polymerase chain reaction (PCR) and
confirmed by DNA sequencing. Dominant-negative mutant of p44ERK cDNA
(DN-ERK) was produced by PCR using primers designed to produce a lysine
(AAG) 
arginine (CGG) substitution at lysine 72 in the ATP-binding
site of W-ERK.21 The
mutation was confirmed by DNA sequencing. The dual activating
phosphorylation sites in p44ERK (T203 and Y205) were
not mutated. Like DN-ERK, a dominant-negative mutant of p46JNK cDNA
(DN-JNK) was produced by PCR using primers designed to produce a lysine
(AAG) arginine (CGG) substitution at lysine 52 in the ATP-binding
site of W-JNK.22 The
dual-activating phosphorylation sites in p46JNK (T183
and Y185) were not mutated. DN-ERK and DN-JNK cannot transfer phosphate
and so have negligible catalytic efficiency of the enzymes (see online
Figures 1
and 2 available in the data supplement at
http://www.circresaha.org), as
described.21 22
W-ERK, W-JNK, DN-ERK, and DN-JNK were tagged hemagglutinin (HA) in the
site of NH2 terminus.
|
|
W-ERK, W-JNK, DN-ERK, and DN-JNK with HA tag were ligated into the blunted EcoRI site of pUC-CAGGS expression plasmid (pUC/W-ERK, pUC/W-JNK, pUC/DN-ERK, and pUC/DN-JNK, respectively). The pUC-CAGGS vector lacking cDNA served as control vector (vehicle).
Preparation of HVJ Liposomes
The preparation of HVJ liposomes has been described
in detail
previously.16 17 19 20
In Vivo Gene Transfer and Balloon
Injury
The first experiments were performed to examine the
effects of DN-ERK and DN-JNK on neointimal formation after
balloon injury. Rats were anesthetized with sodium
pentobarbital (40 mg/kg IP). The left common carotid artery 20 mm
proximal to the carotid bifurcation and the left internal carotid
artery at the orifice were temporary occluded by aneurysmal
clips. The external carotid artery was ligated at the exposed distal
end. To achieve the in vivo gene transfer, the common carotid artery
segment was isolated by temporary clips. An infusion cannula was
introduced into the segment of the common carotid artery through a
small window opened in the external carotid artery. The HVJ-liposome
complex with pUC/DN-ERK, pUC/DN-JNK, or pUC-CAGGS vector as control was
infused into the closed luminal segment of common carotid artery and
incubated for 15 minutes at room temperature, as previously
reported.17 19 20
After incubation, the infused fluid of HVJ-liposome complex was
removed, the external carotid artery was ligated at the orifice, the
blood flow to the common and internal carotid arteries was restored by
releasing the clips, and the wound was closed. At 2 days after gene
transfer, the endothelial denudation of the left common
carotid artery was carried out by 3 passages of a Fogarty 2F balloon
catheter (Baxter Healthcare) through the left
femoral artery, as previously
described.12 23
In separate experiments, to examine the synergy of DN-ERK and DN-JNK,
we compared the effect of gene transfer of combined DN-ERK and DN-JNK
on intimal hyperplasia with that of DN-ERK or DN-JNK alone at 14 days
after balloon injury.
The second experiments were performed to examine the effects of W-ERK and W-JNK on neointimal formation after injury. The HVJ-liposome complex with pUC/W-ERK, pUC/W-JNK, or pUC-CAGGS vector (control) was incubated within the lumen of left common carotid artery for 15 minutes in the same manner as the first experiments. At 2 days after gene transfer, the endothelial denudation of the left common carotid artery was carried out, as previously described.12 23
Preparation of Arterial Protein
Extracts for Protein Kinase Assay
Our methods have been described in detail
previously.12 Briefly,
carotid arteries in each group were pooled from 4 to 5 rats to minimize
animal-to-animal and procedure variability, and the pooled arteries
were homogenized in lysis
buffer.12
Measurement of Arterial ERK and JNK
Activities
ERK and JNK activities were measured by using an
in-gel kinase method, as previously described in
detail.12 24 25
Western Blot Analysis
Western blot analysis was performed as
previously described in
detail.12 Briefly,
arterial protein extracts (60 µg protein), prepared as
described above, were boiled for 5 minutes in Laemmli sample buffer and
then electrophoresed on a SDS polyacrylamide gel (12%), and
the separated proteins were electrophoretically transferred to
Hybond-PVDF membranes
(Amersham Life Sciences). Nonspecific background
was blocked by incubating the membrane with 5% bovine serum
albumin in Tris-buffered saline (pH 7.6) containing 0.1%
Tween 20 (TBS-T) at 4°C overnight. The
membrane was then incubated with rabbit polyclonal anti-HA antibody
(Covance, Research Products, Inc) (5 µg/mL) for 1 hour at room
temperature, washed 4 times with TBS-T, and then incubated with
horseradish peroxidase–conjugated donkey anti-rabbit immunoglobulin
(Amersham). After additional washing with TBS-T,
the membrane was treated with ECL reagent
(Amersham), and chemiluminescence was detected
by exposure to Hyperfilm-ECL. Blots were quantified using model GS-700
imaging densitometer with Macintosh Software for
Image Analysis Systems (Multi-Analyst Version 1.0)
(Bio-Rad Laboratories).
Measurement of Intimal/Medial Area
Ratio
For the estimation of intimal/medial area (I/M)
ratio, rats were anesthetized with ether, carotid arteries were
fixed by perfusion of 10% (wt/vol) formaldehyde for 15 minutes under
constant pressure, and the middle portion of the left common carotid
artery (6-mm length) was removed from each animal, divided into six
1-mm-thick specimens, embedded in paraffin, and sectioned at 3-µm
thickness. The 3-µm cross sections were stained with Elastica Van
Gieson and H&E. The intimal and the medial areas of each cross section
were measured with a light microscope connected to the image
analyzer in a blinded fashion. In each animal, the mean intimal
and medial areas of each artery were calculated from these 6
sections.
BrdU Immunohistochemistry and Morphometric
Analyses
We measured the percentages of BrdU-positive cells at
7 days after injury and the nuclei number at 14 days, as previously
reported.26 In brief, for
BrdU immunohistochemistry, rats were
intraperitoneally injected with 100 mg/kg BrdU at
24 hours and 1 hour before being killed. In the same way as the
estimation of I/M ratio, the left carotid arteries were fixed by
perfusion of 10% (wt/vol) formaldehyde for 15 minutes, removed,
embedded in paraffin, and sectioned at 3-µm thickness. In each
animal, 6 sections were examined in a blinded fashion. BrdU
immunohistochemistry was performed with a mouse anti-BrdU monoclonal
antibody (Amersham) and LSAB2 kit
(Dako Japan Co, Ltd).
Total cell number of the intima and media at 14 days after injury was estimated for each section by multiplying the intimal and medial cross-sectional areas, respectively, by the number of nuclei per square millimeter, which was calculated by counting nuclei and is in three representative high-power fields (x200), as previously described.26
Direct Effects of Dominant-Negative Mutant of
ERK and JNK on Vascular Smooth Muscle Cell Proliferation In
Vitro
Recombinant replication–defective E1- and
E3-adenoviral vectors expressing DN-ERK or DN-JNK were constructed
using an adenovirus expression vector kit (Takara Biomedicals)
according to the method of Miyake et
al.27 cDNA encoding DN-ERK
or DN-JNK was placed into a cassette cosmid vector PaxCAwt, which
possesses CAG promoter comprising a cytomegalovirus enhancer, chicken
ß-actin promoter, and rabbit ß-globin poly A signal. A recombinant
adenovirus was constructed by in vitro homologous recombination in 293
cells using the above cosmid vector PaxCAwt containing DN-ERK or DN-JNK
cDNA and the adenovirus DNA-terminal protein complex. Recombinant
adenoviruses containing bacterial ß-galactosidase gene was also
constructed as negative control of DN-ERK or DN-JNK in the same way.
The titer of the virus was determined by limiting dilution in 293 cells
and expressed as plaque-forming units.
Rat aortic SMCs were prepared from thoracic aortas of male Sprague-Dawley rats by using the collagenase digestion method and cultured, as described.28 For all experiments, rat aortic SMCs from passages 4 to 7 were used. SMCs were grown to 70% to 80% confluence and then made quiescent by incubation with DMEM containing 0.1% FBS for 48 hours and stimulated with addition of 2% serum. In vitro gene transfer to aortic SMCs was carried out by incubation with the adenoviral vector with multiplicity of infection of 50 in DMEM containing 0.1% FBS for 1 hour at 37°C, 5% CO2, and 95% air. Then SMCs were made quiescent for 48 hours before being assessed for the expression and the effect of the transferred gene. SMCs in 6-well plates were stimulated by 2% serum for 19 hours and pulsed with 1 µCi/mL [3H]thymidine for 5 hours. Then cells were washed twice with PBS, incubated for 5 minutes in 5% trichloroacetic acid, washed by methanol, and dissolved in 99% formic acid. The incorporation of [3H]thymidine into trichloroacetic acid–insoluble material was measured by liquid scintillation spectrophotometer. For the assay of cell growth, SMCs in 60-mm plates were stimulated by 5% serum, and cell number was counted by Coulter counter (Beckman).
Statistical Analysis
All data are presented as mean±SEM.
Statistical significance was determined with one-way ANOVA followed by
Duncan multiple-range comparison test using Super ANOVA (Abacus
Concepts, Inc). Differences were considered statistically significant
at a value of
P<0.05.
Results
Effects of Dominant-Negative Mutants on
Arterial ERK and JNK Activities In Vivo
To distinguish between the dominant-negative mutant and
endogenous kinase, we used DN-ERK–encoded and
DN-JNK–encoded HA-tag in the site of its NH2 terminus. To confirm the
successful gene transfer of these dominant-negative mutants into
carotid artery in vivo with HVJ-liposome method, carotid arteries,
subjected to gene transfer of pUC/DN-ERK, pUC/DN-JNK, or pUC-CAGGS
before 2 days, were removed at 5 minutes and 2, 4, and 7 days after
balloon injury. As shown in
Figure 1A
, the Western blot analysis with anti-HA
antibody showed the single band corresponding to the same molecular
weight as p44ERK (44 kDa) in arterial protein extracts
subjected to gene transfer of DN-ERK but no band in those of pUC-CAGGS
(control vector), confirming the successful expression of DN-ERK within
arterial cells at 2, 4, and 7 days after injury. Being in
good agreement with our previous
report,12 p44ERK and p42ERK
were remarkably activated at 5 minutes after injury, and this
activation was significantly inhibited by gene transfer of DN-ERK
(P<0.01).
As in the case of DN-ERK gene transfer,
Figure 1B showed that DN-JNK gene transfer allowed for the
significant expression of the protein in arterial tissues
at 2, 4, and 7 days after injury, and the peaked activation of
arterial JNK at 5 minutes after injury was successfully
suppressed by gene transfer of
DN-JNK(P<0.01).
Effects of Dominant-Negative Mutants of ERK and
JNK on Neointimal Formation
As shown in
Figures 2 and 3, remarkable neointimal formation
was observed in the vehicle-transfected group at 14 and 28 days after
injury. DN-ERK and DN-JNK significantly decreased the I/M ratio
(0.62±0.09 and 0.43±0.09, respectively) compared with vehicle
(pUC-CAGGS) (0.97±0.05)
(P<0.01;
Figure 3A) at 14 days. Even at 28 days, DN-ERK and DN-JNK
significantly suppressed neointimal formation
(P<0.01;
Figure 3B). On the other hand, DN-ERK or DN-JNK did not
affect the medial areas at 14 or 28 days.
|
Total intimal nuclei number per section in arterial segments transfected with DN-ERK (891±77) or DN-JNK (857±90) was similar and significantly smaller than that of vehicle-transfected arterial segment (1808±134) (P<0.01). There was no significant difference among the three groups transfected with vehicle, DN-ERK, and DN-JNK with respect to medial nuclei number (681±28, 711±36, and 735±37, respectively).
In separate experiments, we compared the effect of combined DN-ERK and DN-JNK gene transfer on intimal hyperplasia with that of each mutant alone at 14 days after balloon injury. The I/M ratio at 14 days after balloon injury was 0.95±0.06, 0.69±0.05, 0.64±0.06, and 0.52±0.05 in vehicle and groups treated with DN-ERK, DN-JNK, and combined DN-ERK and DN-JNK, respectively (each n=7). DN-ERK, DN-JNK, and their combination all significantly reduced the I/M ratio compared with vehicle (P<0.01). Although the combination of these genes decreased the I/M ratio more than DN-ERK alone (P<0.01), there was no significant difference between DN-JNK alone and combined DN-ERK and DN-JNK.
Effects of DN-ERK and DN-JNK on SMC
Proliferation In Vivo
To estimate SMC proliferation, we measured the intimal
and medial BrdU index at 7 days after injury. As shown in
Figures 4 and 5A, the percentages of BrdU-positive cells in
the neointima from groups transfected with DN-ERK
(20.2±2.2%) or DN-JNK (18.7±3.2%) were smaller than those of the
control group (36.9±3.9%)
(P<0.01).
|
|
As shown in
Figure 5B, there was no BrdU-positive cell in the media of
noninjured arteries. The percentages of BrdU-positive cells in the
media from groups transfected with DN-ERK (3.3±0.4%) and DN-JNK
(3.2±0.6%) were smaller than the percentage of the control group
(8.6±1.2%)
(P<0.01).
Effects of Wild-Type ERK and JNK on
Neointimal Formation
We examined the effects of W-ERK or W-JNK transfection
on neointimal formation after balloon injury. As shown in
Figures 6 and 7A, W-ERK and W-JNK transfection (1.19±0.09
and 1.21±0.11, respectively) significantly increased the I/M ratio
compared with pUC-CAGGS transfection (0.76±0.06). Medial areas were
not affected by transfection of W-ERK, W-JNK, or both
(Figure 7B).
|
|
Inhibitory Effects of
Dominant-Negative Mutant ERK and JNK on Vascular Smooth Muscle Cell
Proliferation In Vitro
To confirm that ERK and JNK are directly involved in
vascular SMC proliferation, we examined the effects of DN-ERK and
DN-JNK on vascular SMC proliferation in vitro.
Figure 8 shows the effect of these dominant-negative mutants
on the kinase activity, 3H-thymidine
incorporation, and cell number in cultured rat aortic SMCs stimulated
with serum. Stimulation of aortic SMCs with 2% serum significantly
activated ERK and JNK by 6.4-fold (n=3,
P<0.01) and 9.9-fold (n=3,
P<0.01), respectively, and
increased both 3H-thymidine incorporation
and cell numbers (P<0.01).
These increases in ERK and JNK activities were inhibited by DN-ERK by
90% (n=3, P<0.01) and DN-JNK
by 67% (n=3, P<0.01),
respectively
(Figures 8A and 8B, respectively). DN-ERK and DN-JNK inhibited
serum-induced increase in [3H]thymidine
incorporation by 51% and 60%, respectively
(Figure 8C) and also attenuated the increase in cell number
by 86% and 89%, respectively
(Figure 8D). On the other hand, LacZ gene transfer did not
affect ERK or JNK activity, the increase in
[3H]thymidine incorporation, or cell
number in aortic SMCs stimulated with
serum.
|
Discussion
The major findings of this work were that gene transfer of either DN-ERK or DN-JNK significantly prevented neointimal formation after balloon injury and inhibited vascular SMC proliferation in vitro and in vivo, indicating that both ERK and JNK are involved in intimal hyperplasia in vivo.
We and other groups of investigators have reported that vascular ERK and JNK are significantly activated by balloon injury,12 13 14 the injection of angiotensin II24 or other hypertensive agents,29 and chronic hypertension.30 All these findings led us to propose that the activation of ERK and JNK may trigger a series of complex molecular events leading to the neointimal formation. However, the investigation of the in vivo blockade of these MAPKs has been hampered by the absence of their specific and potent pharmacologic inhibitors, and the significance of activation of these kinases in vascular diseases in vivo remains to be defined.
In the present study, to specifically inhibit the activation of vascular endogenous ERK and JNK in vivo, we produced dominant-negative mutants of ERK and JNK. To transfect these mutant genes into rat carotid artery, we used the HVJ-liposome technique,16 17 19 20 because the use of HVJ-liposome method allows for the effective gene transfer into medial SMCs of the intact carotid artery not subjected to endothelial denudation.31 To distinguish the transfected dominant-negative mutant of ERK or JNK from the endogenous kinase, the dominant-negative mutants were HA-tagged. Western blot analysis with anti-HA antibody and in-gel kinase assay confirmed that DN-ERK and DN-JNK were effectively expressed within the arterial cells and the expressed mutants could potently inhibit the activation of their respective kinase after balloon injury. Thus, our present method allowed us to elucidate the direct role of these MAPKs in neointimal formation after balloon injury.
Despite in vitro solid evidence for the involvement of ERK
in cell growth, the role of ERK in vivo is poorly understood. In the
present study, we obtained the first evidence that the inhibition
of ERK activation by gene transfer of DN-ERK significantly suppressed
the neointimal formation, whereas wild-type ERK gene
transfer accelerated the neointima thickening, confirming
the contribution of ERK activation to neointimal formation
after balloon injury. As shown by labeling index of BrdU-positive
nuclei and total cell counting, gene transfer of DN-ERK suppressed SMC
proliferation in either the intima or the media and reduced intimal
cell number. This observation, taken together with the in vitro results
that DN-ERK inhibited cultured vascular SMC proliferation
(Figure 8), demonstrated that the suppression of SMC
proliferation was involved in the inhibition of intimal thickening by
DN-ERK. However, additional study is needed to elucidate the precise
mechanism underlying the inhibition of neointima, because
the possible contribution of migration or apoptosis cannot be
excluded.
On the other hand, Koyama et al,14 who examined the effects of PD98059, a selective inhibitor of MEK-1 on SMC proliferation after balloon injury of rat carotid artery, reported that PD98059 blocks medial cell replication but not intimal cell replication in injured artery, being in disagreement with our present data on significant inhibition of replication of intimal cells as well as medial cells by DN-ERK. However, because this group of investigators did not examine the inhibitory effect of PD98059 on arterial ERK activity at any earlier time points than 30 minutes after balloon injury, it was uncertain in their study whether PD98059 could inhibit arterial ERK activation at the peak time point (5 minutes) after balloon injury. Furthermore, because PD98059 is not such a potent inhibitor, it is unclear whether this compound is sufficiently effective in in vivo conditions.32 Thus, the failure of inhibition of SMC proliferation in the intima after balloon injury by PD98059 is possibly attributable to the insufficient blockade of ERK activation by this compound in vivo. Moreover, it cannot be excluded that MEK inhibition with PD98059 may not only inhibit ERK activation but also affect other protein kinase cascades.33 Thus, our present study provided the first evidence for the important role of ERK activation in neointimal hyperplasia after balloon injury.
JNK, belonging to another MAPK family, activates c-Jun by phosphorylation at its Ser 63/7334 and has different upstream and downstream cascades from ERK.9 10 11 As recently reviewed,15 JNK activation has diverse function. For example, the activation of the JNK pathway has been reported to play a positive role in cell growth in fibroblasts, T cells, and cardiac myocytes, whereas other studies have shown the negative role of JNK in cell proliferation and the apoptotic function of JNK in hippocampal neurons or PC12 cells. Therefore, whether JNK activation leads to cell proliferation or apoptosis depends on the cell type and the signaling pathways that are simultaneously activated.15 However, the significance of JNK activation in injured artery in vivo remains unknown. In the present study, of note are the observations that gene transfer of DN-JNK prevented SMC proliferation and neointimal formation after balloon injury, whereas wild-type JNK gene transfer enhanced neointima formation. Furthermore, our present work showed that DN-JNK suppressed cultured vascular SMC proliferation in vitro. These results demonstrated that as in the case of ERK, JNK activation participated in neointimal formation, at least in part by stimulating SMC proliferation. As in DN-ERK, DN-JNK gene transfer did not alter the medial area despite the suppression of medial SMC proliferation. These findings may be attributable to the fact that the medial area is affected not only by medial SMC proliferation but also by other events, such as medial SMC apoptosis, extracellular matrix accumulation, and SMC migration from the media to the intima, although additional study is needed to elucidate this point.
Study Limitation
As in the case of most previous studies concerning the
effects of in vivo gene transfer with adenovirus vector or HVJ liposome
on arterial
hyperplasia,6 in this work,
the duration of isolation of arterial segment for gene
transfer was longer than that accepted in clinical situation.
Therefore, the development of more effective gene transfer technique is
essential for the clinical application. Furthermore,
arterial restenosis in humans after balloon injury
generally occurs at longer periods than in rats. Thus, additional study
is needed to determine whether our present findings can apply to
human restenosis.
In conclusion, we obtained the first evidence that specific blockade of ERK or JNK activation by gene transfer of their dominant-negative mutants prevents SMC proliferation and neointimal thickening in balloon-injured artery, demonstrating that either ERK or JNK activation triggers a series of molecular events leading to neointimal hyperplasia in vivo. Thus, our work provides new insight into the molecular mechanism of neointimal hyperplasia. We propose that these MAPKs are the new therapeutic targets for the prevention of vascular diseases. However, additional study is needed to elucidate the detailed mechanism underlying neointimal hyperplasia induced by these MAPKs.
Acknowledgments
This work was supported in part by a Grant-in-Aid for Scientific Research (09470527 and 11670098) from the Ministry of Education, Science, Sports and Culture and the Hoh-ansha Foundation.
Footnotes
Original received November 27, 2000; revision received April 10, 2001; accepted April 10, 2001.
References
1. Clowes AW, Reidy MA, Clowes MM. Kinetics of cellular proliferation after arterial injury, I: smooth muscle cell growth in the absence of endothelium. Lab Invest. 1983;49:327–333.
2. Clowes AW, Schwartz SM. Significance of quiescent smooth muscle migration in the injured rat carotid artery. Circ Res. 1985;56:139–145.
3. Libby P, Schwartz D, Brogi E, Tanaka H, Clinton SK. A cascade model for restenosis: a special case of atherosclerosis progression. Circulation. 1992;86:III47–III52.
4. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801–809.
5. Schwartz RS, Holmes DR Jr, Topol EJ. The restenosis paradigm revisited: an alternative proposal for cellular mechanisms. J Am Coll Cardiol. 1992;20:1284–1293.
6. Baek S, March KL. Gene therapy for restenosis: getting nearer the heart of the matter. Circ Res. 1998;82:295–305.
7. DeYoung MB, Dichek DA. Gene therapy for restenosis: are we ready? Circ Res. 1998;82:306–313.
8. Kibbe MR, Billiar TR, Tzeng E. Gene therapy for restenosis. Circ Res. 2000;86:829–833.
9. Cano E, Mahadevan LC. Parallel signal processing among mammalian MAPKs. Trends Biochem Sci. 1995;20:117–122.
10. Davis RJ. The mitogen-activated protein kinase signal transduction pathway. J Biol Chem. 1993;268:14553–14556.
11. Force T, Pombo CM, Avruch JA, Bonventre JV, Kyriakis JM. Stress-activated protein kinases in cardiovascular disease. Circ Res. 1996;78:947–953.
12. Kim S, Izumi Y, Yano M, Hamaguchi A, Miura K, Yamanaka S, Miyazaki H, Iwao H. Angiotensin blockade inhibits activation of mitogen-activated protein kinases in rat balloon-injured artery. Circulation. 1998;97:1731–1737.
13. Hu Y, Cheng L, Hochleitner BW, Xu Q. Activation of mitogen-activated protein kinases (ERK/JNK) and AP-1 transcription factor in rat carotid arteries after balloon injury. Arterioscler Thromb Vasc Biol. 1997;17:2808–2816.
14. Koyama H, Olson NE, Dastvan FF, Reidy MA. Cell replication in the arterial wall: activation of signaling pathway following in vivo injury. Circ Res. 1998;82:713–721.
15. Leppa S, Bohmann D. Diverse functions of JNK signaling and c-Jun in stress response and apoptosis. Oncogene. 1999;18:6158–6162.
16. Suzuki J, Isobe M, Morishita R, Aoki M, Horie S, Okubo Y, Kaneda Y, Sawa Y, Matsuda H, Ogihara T, Sekiguchi M. Prevention of graft coronary arteriosclerosis by antisense cdk2 kinase oligonucleotide. Nat Med. 1997;3:900–903.
17.
Morishita R,
Sugimoto T, Aoki M, Kida I, Tomita N, Moriguchi A, Maeda K, Sawa Y,
Kaneda Y, Higaki J, Ogihara T. In vivo transfection of cis element
"decoy" against nuclear factor-
B binding site prevents
myocardial infarction. Nat Med. 1997;3:894–899.
18. Morishita R, Higaki J, Aoki M, Hayashi S, Kida I, Kaneda Y, Ogihara T. Novel strategy of gene therapy in cardiovascular disease with HVJ-liposome method. Contrib Nephrol. 1996;118:254–264.
19. Morishita R, Gibbons GH, Ellison KE, Nakajima M, von-der-Leyen H, Zhang L, Kaneda Y, Ogihara T, Dzau VJ. Intimal hyperplasia after vascular injury is inhibited by antisense cdk 2 kinase oligonucleotides. J Clin Invest. 1994;93:1458–1464.
20. Morishita R, Gibbons GH, Ellison KE, Nakajima M, Zhang L, Kaneda Y, Ogihara T, Dzau VJ. Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc Natl Acad Sci U S A. 1993;90:8474–8478.
21. Robbins DJ, Zhen E, Owaki H, Vanderbilt CA, Ebert D, Geppert TD, Cobb MH. Regulation and properties of extracellular signal-regulated protein kinases 1 and 2 in vitro. J Biol Chem. 1993;268:5097–5106.
22. Li YS, Shyy JY, Li S, Lee J, Su B, Karin M, Chien S. The Ras-JNK pathway is involved in shear-induced gene expression. Mol Cell Biol. 1996;16:5947–5954.
23. Kim S, Kawamura M, Wanibuchi H, Ohta K, Hamaguchi A, Omura T, Yukimura T, Miura K, Iwao H. Angiotensin II type I receptor blockade inhibits the expression of immediate-early genes and fibronectin in rat injured artery. Circulation. 1995;92:88–95.
24. Yano M, Kim S, Izumi Y, Yamanaka S, Iwao H. Differential activation of cardiac c-Jun amino-terminal kinase and extracellular signal-regulated kinase in angiotensin II–mediated hypertension. Circ Res. 1998;83:752–760.
25. Izumi Y, Kim S, Murakami T, Yamanaka S, Iwao H. Cardiac mitogen-activated protein kinase activities are chronically increased in stroke-prone hypertensive rats. Hypertension. 1998;31:50–56.
26. Negoro N, Hoshiga M, Seto M, Kohbayashi E, Ii M, Fukui R, Shibata N, Nakakoji T, Nishiguchi F, Sasaki Y, Ishihara T, Ohsawa N. The kinase inhibitor fasudil (HA-1077) reduces intimal hyperplasia through inhibiting migration and enhancing cell loss of vascular smooth muscle cells. Biochem Biophys Res Commun. 1999;262:211–215.
27. Miyake S, Makimura M, Kanegae Y, Harada S, Sato Y, Takamori K, Tokuda C, Saito I. Efficient generation of recombinant adenoviruses using adenovirus DNA- terminal protein complex and a cosmid bearing the full-length virus genome. Proc Natl Acad Sci U S A. 1996;93:1320–1324.
28. Hamaguchi A, Kim S, Izumi Y, Zhan Y, Yamanaka S, Iwao H. Contribution of extracellular signal–regulated kinase to angiotensin II–induced transforming growth factor-ß1 expression in vascular smooth muscle cells. Hypertension. 1999;34:126–131.
29. Xu Q, Liu Y, Gorospe M, Udelsman R, Holbrook NJ. Acute hypertension activates mitogen-activated protein kinases in arterial wall. J Clin Invest. 1996;97:508–514.
30. Kim S, Murakami T, Izumi Y, Yano M, Miura K, Yamanaka S, Iwao H. Extracellular signal-regulated kinase and c-Jun NH2-terminal kinase activities are continuously and differentially increased in aorta of hypertensive rats. Biochem Biophys Res Commun. 1997;236:199–204.
31. Yonemitsu Y, Kaneda Y, Morishita R, Nakagawa K, Nakashima Y, Sueishi K. Characterization of in vivo gene transfer into the arterial wall mediated by the Sendai virus (hemagglutinating virus of Japan) liposomes: an effective tool for the in vivo study of arterial diseases. Lab Invest. 1996;75:313–323.
32. Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci U S A. 1995;92:7686–7689.
33. Xi XP, Graf K, Goetze S, Fleck E, Hsueh WA, Law RE. Central role of the MAPK pathway in Ang II-mediated DNA synthesis and migration in rat vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 1999;19:73–82.
34. Derijard B, Hibi M, Wu IH, Barrett T, Su B, Deng T, Karin M, Davis RJ. JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell. 1994;76:1025–1037.
This article has been cited by other articles:
 |
|
 |
|
  C.-S. Lee, Y.-W. Kwon, H.-M. Yang, S.-H. Kim, T.-Y. Kim, J. Hur, K.-W. Park, H.-J. Cho, H.-J. Kang, Y.-B. Park, et al. New Mechanism of Rosiglitazone to Reduce Neointimal Hyperplasia: Activation of Glycogen Synthase Kinase-3{beta} Followed by Inhibition of MMP-9 Arterioscler Thromb Vasc Biol, April 1, 2009; 29(4): 472 - 479. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Matsumoto, P. C. Dimayuga, C. Wang, J. Kirzner, M. Cercek, J. Yano, K.-Y. Chyu, P. K. Shah, and B. Cercek Exogenous heat shock protein-70 inhibits cigarette smoke-induced intimal thickening Am J Physiol Regulatory Integrative Comp Physiol, October 1, 2008; 295(4): R1320 - R1327. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Han, J. Deng, L. Guo, C. Yan, M. Liang, J. Kang, H. Liu, A. M. Graham, and S. Li CREG promotes a mature smooth muscle cell phenotype and reduces neointimal formation in balloon-injured rat carotid artery Cardiovasc Res, June 1, 2008; 78(3): 597 - 604. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Laaksamo, R. Tulamo, M. Baumann, R. Dashti, J. Hernesniemi, S. Juvela, M. Niemela, and A. Laakso Involvement of Mitogen-Activated Protein Kinase Signaling in Growth and Rupture of Human Intracranial Aneurysms Stroke, March 1, 2008; 39(3): 886 - 892. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Julien, P. Wang, C. A. Haller, J. Wen, and E. L. Chaikof Mechanical strain regulates syndecan-4 expression and shedding in smooth muscle cells through differential activation of MAP kinase signaling pathways Am J Physiol Cell Physiol, January 1, 2007; 292(1): C517 - C525. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Walcher, C. Babiak, P. Poletek, S. Rosenkranz, H. Bach, S. Betz, R. Durst, M. Grub, V. Hombach, J. Strong, et al. C-Peptide Induces Vascular Smooth Muscle Cell Proliferation: Involvement of Src-Kinase, Phosphatidylinositol 3-Kinase, and Extracellular Signal-Regulated Kinase 1/2 Circ. Res., November 24, 2006; 99(11): 1181 - 1187. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Yokouchi, Y. Numaguchi, R. Kubota, M. Ishii, H. Imai, R. Murakami, Y. Ogawa, T. Kondo, K. Okumura, D. E. Ingber, et al. l-Caldesmon Regulates Proliferation and Migration of Vascular Smooth Muscle Cells and Inhibits Neointimal Formation After Angioplasty Arterioscler Thromb Vasc Biol, October 1, 2006; 26(10): 2231 - 2237. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Koka, W. Wang, X. R. Huang, S. Kim-Mitsuyama, L. D. Truong, and H. Y. Lan Advanced Glycation End Products Activate a Chymase-Dependent Angiotensin II-Generating Pathway in Diabetic Complications Circulation, March 14, 2006; 113(10): 1353 - 1360. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Shen, S. P. Halenda, M. Sturek, and P. A. Wilden Cell-Signaling Evidence for Adenosine Stimulation of Coronary Smooth Muscle Proliferation via the A1 Adenosine Receptor Circ. Res., September 16, 2005; 97(6): 574 - 582. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Deaton, C. Su, T. G. Valencia, and S. R. Grant Transforming Growth Factor-{beta}1-induced Expression of Smooth Muscle Marker Genes Involves Activation of PKN and p38 MAPK J. Biol. Chem., September 2, 2005; 280(35): 31172 - 31181. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L.-J. Min, M. Mogi, J.-M. Li, J. Iwanami, M. Iwai, and M. Horiuchi Aldosterone and Angiotensin II Synergistically Induce Mitogenic Response in Vascular Smooth Muscle Cells Circ. Res., September 2, 2005; 97(5): 434 - 442. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Ollinger, M. Bilban, A. Erat, A. Froio, J. McDaid, S. Tyagi, E. Csizmadia, A. V. Graca-Souza, A. Liloia, M. P. Soares, et al. Bilirubin: A Natural Inhibitor of Vascular Smooth Muscle Cell Proliferation Circulation, August 16, 2005; 112(7): 1030 - 1039. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. G. Egan, C. L. Wainwright, R. M. Wadsworth, and G. F. Nixon PDGF-induced signaling in proliferating and differentiated vascular smooth muscle: Effects of altered intracellular Ca2+ regulation Cardiovasc Res, August 1, 2005; 67(2): 308 - 316. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Katsuma, N. Hatae, T. Yano, Y. Ruike, M. Kimura, A. Hirasawa, and G. Tsujimoto Free Fatty Acids Inhibit Serum Deprivation-induced Apoptosis through GPR120 in a Murine Enteroendocrine Cell Line STC-1 J. Biol. Chem., May 20, 2005; 280(20): 19507 - 19515. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-M. Li, M. Iwai, T.-X. Cui, L.-J. Min, M. Tsuda, J. Iwanami, J. Suzuki, M. Mogi, and M. Horiuchi Effect of Azelnidipine on Angiotensin II-Mediated Growth-Promoting Signaling in Vascular Smooth Muscle Cells Mol. Pharmacol., May 1, 2005; 67(5): 1666 - 1673. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Sakamoto, T. Murata, H. Chuma, M. Hori, and H. Ozaki Fluvastatin Prevents Vascular Hyperplasia by Inhibiting Phenotype Modulation and Proliferation Through Extracellular Signal-Regulated Kinase 1 and 2 and p38 Mitogen-Activated Protein Kinase Inactivation in Organ-Cultured Artery Arterioscler Thromb Vasc Biol, February 1, 2005; 25(2): 327 - 333. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Katakami, H. Kaneto, H. Hao, Y. Umayahara, Y. Fujitani, K. Sakamoto, S.-i. Gorogawa, T. Yasuda, D. Kawamori, Y. Kajimoto, et al. Role of Pim-1 in Smooth Muscle Cell Proliferation J. Biol. Chem., December 24, 2004; 279(52): 54742 - 54749. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Gennaro, C. Menard, S.-E. Michaud, D. Deblois, and A. Rivard Inhibition of Vascular Smooth Muscle Cell Proliferation and Neointimal Formation in Injured Arteries by a Novel, Oral Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Inhibitor Circulation, November 23, 2004; 110(21): 3367 - 3371. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Calabro, I. Samudio, J. T. Willerson, and E. T.H. Yeh Resistin Promotes Smooth Muscle Cell Proliferation Through Activation of Extracellular Signal-Regulated Kinase 1/2 and Phosphatidylinositol 3-Kinase Pathways Circulation, November 23, 2004; 110(21): 3335 - 3340. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. Behera, C. M. Thorpe, J. M. Kidder, W. Smith, E. Hildebrand, and L. T. Hu Borrelia burgdorferi-Induced Expression of Matrix Metalloproteinases from Human Chondrocytes Requires Mitogen-Activated Protein Kinase and Janus Kinase/Signal Transducer and Activator of Transcription Signaling Pathways Infect. Immun., May 1, 2004; 72(5): 2864 - 2871. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. C. Saunders, G. Pintucci, C. S. Bizekis, R. Sharony, K. M. Hyman, F. Saponara, F. G. Baumann, E. A. Grossi, S. B. Colvin, P. Mignatti, et al. Vein graft arterialization causes differential activation of mitogen-activated protein kinases J. Thorac. Cardiovasc. Surg., May 1, 2004; 127(5): 1276 - 1284. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Omura, M. Yoshiyama, S. Kim, R. Matsumoto, Y. Nakamura, Y. Izumi, H. Ichijo, T. Sudo, K. Akioka, H. Iwao, et al. Involvement of Apoptosis Signal-Regulating Kinase-1 on Angiotensin II-Induced Monocyte Chemoattractant Protein-1 Expression Arterioscler Thromb Vasc Biol, February 1, 2004; 24(2): 270 - 275. [Abstract] [Full Text]
|
|
|
|
|
|
Y. Izumi, S. Kim, M. Yoshiyama, Y. Izumiya, K. Yoshida, A. Matsuzawa, H. Koyama, Y. Nishizawa, H. Ichijo, J. Yoshikawa, et al. Activation of Apoptosis Signal-Regulating Kinase 1 in Injured Artery and Its Critical Role in Neointimal Hyperplasia Circulation, December 2, 2003; 108(22): 2812 - 2818. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Kishore, C. Luedemann, E. Bord, D. Goukassian, and D. W. Losordo Tumor Necrosis Factor-Mediated E2F1 Suppression in Endothelial Cells: Differential Requirement of c-Jun N-Terminal Kinase and p38 Mitogen-Activated Protein Kinase Signal Transduction Pathways Circ. Res., November 14, 2003; 93(10): 932 - 940. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Yamada, S. Kim, K. Egashira, M. Takeya, T. Ikeda, O. Mimura, and H. Iwao Molecular Mechanism and Role of Endothelial Monocyte Chemoattractant Protein-1 Induction by Vascular Endothelial Growth Factor Arterioscler Thromb Vasc Biol, November 1, 2003; 23(11): 1996 - 2001. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Tallant and M. A. Clark Molecular Mechanisms of Inhibition of Vascular Growth by Angiotensin-(1-7) Hypertension, October 1, 2003; 42(4): 574 - 579. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Huang, S. B. Petkova, A. W. Cohen, B. Bouzahzah, J. Chan, J.-n. Zhou, S. M. Factor, L. M. Weiss, M. Krishnamachary, S. Mukherjee, et al. Activation of Transcription Factors AP-1 and NF-{kappa}B in Murine Chagasic Myocarditis Infect. Immun., May 1, 2003; 71(5): 2859 - 2867. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Zhan, S. Kim, Y. Izumi, Y. Izumiya, T. Nakao, H. Miyazaki, and H. Iwao Role of JNK, p38, and ERK in Platelet-Derived Growth Factor-Induced Vascular Proliferation, Migration, and Gene Expression Arterioscler Thromb Vasc Biol, May 1, 2003; 23(5): 795 - 801. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Kawano, S. Kim, K. Ohta, T. Nakao, H. Miyazaki, T. Nakatani, and H. Iwao Differential Contribution of Three Mitogen-Activated Protein Kinases to PDGF-BB-Induced Mesangial Cell Proliferation and Gene Expression J. Am. Soc. Nephrol., March 1, 2003; 14(3): 584 - 592. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Ahn, R. Morishita, Y. Kaneda, S.-J. Lee, K.-Y. Kwon, S.-Y. Choi, K.-U. Lee, J.-Y. Park, I.-J. Moon, J.-G. Park, et al. Inhibitory Effects of Novel AP-1 Decoy Oligodeoxynucleotides on Vascular Smooth Muscle Cell Proliferation In Vitro and Neointimal Formation In Vivo Circ. Res., June 28, 2002; 90(12): 1325 - 1332. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Khachigian, R. G. Fahmy, G. Zhang, Y. V. Bobryshev, and A. Kaniaros c-Jun Regulates Vascular Smooth Muscle Cell Growth and Neointima Formation after Arterial Injury. INHIBITION BY A NOVEL DNA ENZYME TARGETING c-Jun J. Biol. Chem., June 14, 2002; 277(25): 22985 - 22991. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Zhan, S. Kim, H. Yasumoto, M. Namba, H. Miyazaki, and H. Iwao Effects of Dominant-Negative c-Jun on Platelet-Derived Growth Factor-Induced Vascular Smooth Muscle Cell Proliferation Arterioscler Thromb Vasc Biol, January 1, 2002; 22(1): 82 - 88. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||